MERIT MEDICAL SYSTEMS INC
Business
MERIT MEDICAL SYSTEMS INC designs, develops, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures across cardiology, radiology, oncology, critical care and endoscopy. Its product offerings include vascular access devices, guide wires, introducer sheaths, catheters, embolic microspheres and plugs, drainage systems, spine and oncology devices, endoscopy and pulmonary stents, custom procedural kits, and OEM components and coating services. The company operates through two primary segments—cardiovascular and endoscopy—along with custom procedural solutions and a global OEM division. Merit sells products in the U.S. and internationally through direct sales forces, distributors, independent dealers and OEM partners, supported by global distribution centers.
Summary from filing dated 2025-02-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net sales | 1,516 | 1,357 | 1,257 | 1,151 | 1,075 | |
| Cost of sales | 778 | 713 | 673 | 632 | 589 | |
| Gross profit | 738 | 643 | 584 | 519 | 485 | |
| Selling, general and administrative | 455 | 400 | 374 | 343 | 336 | |
| Research and development | 97 | 87 | 83 | 76 | 71 | |
| Impairment charges | — | — | 270,000 | 2 | 4 | |
| Contingent consideration expense | 984,000 | 443,000 | 2 | 5 | 3 | |
| Acquired in-process research and development | — | — | 2 | 7 | — | |
| Total operating expenses | 554 | 488 | 460 | 432 | 424 | |
| Income from operations | 185 | 156 | 124 | 88 | 61 | |
| Interest income | 15 | 26 | 2 | 439,000 | 769,000 | |
| Interest expense | −26 | −31 | −16 | −6 | — | |
| Other (expense) income - net | −2 | −711,000 | 1 | 966,000 | −3 | |
| Total other expense - net | −14 | −6 | −12 | −5 | −7 | |
| Income before income taxes | 171 | 150 | 112 | 83 | 54 | |
| Income tax expense | 42 | 30 | 18 | 8 | 5 | |
| Net income | 128 | 120 | 94 | 75 | 48 | |
| Basic (in dollars per share) | 2.17 | 2.07 | 1.64 | 1.31 | 0.86 | |
| Diluted (in dollars per share) | 2.13 | 2.03 | 1.62 | 1.29 | 0.84 | |
| Basic (in shares) | 59 | 58 | 58 | 57 | 56 | |
| Diluted (in shares) | 60 | 59 | 58 | 58 | 57 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 446 | 377 | 587 | 58 | 68 | |
| Trade receivables - net of allowance for credit losses - 2025 - $10,136 and 2024 - $9,729 | 204 | 190 | 178 | 165 | 152 | |
| Other receivables | 18 | 17 | 11 | 13 | 18 | |
| Inventories | 334 | 306 | 304 | 266 | 222 | |
| Prepaid expenses and other current assets | 31 | 29 | 24 | 22 | 16 | |
| Prepaid income taxes | 5 | 3 | 4 | 4 | 4 | |
| Income tax refund receivables | 2 | 2 | 859,000 | 779,000 | 3 | |
| Total current assets | 1,040 | 924 | 1,108 | 529 | 482 | |
| Land and land improvements | 30 | 26 | 26 | 26 | 25 | |
| Buildings | 200 | 192 | 191 | 189 | 190 | |
| Manufacturing equipment | 365 | 341 | 317 | 299 | 278 | |
| Furniture and fixtures | 61 | 61 | 63 | 61 | 61 | |
| Leasehold improvements | 65 | 59 | 54 | 50 | 46 | |
| Construction-in-progress | 83 | 59 | 61 | 61 | 51 | |
| Total property and equipment | 805 | 738 | 713 | 686 | 652 | |
| Less accumulated depreciation | −376 | −352 | −329 | −303 | −281 | |
| Property and equipment - net | 428 | 386 | 384 | 383 | 372 | |
| Goodwill | 507 | 464 | 382 | 360 | 362 | |
| Deferred income tax assets | 7 | 16 | 7 | 7 | 6 | |
| Right-of-use operating lease assets | 88 | 66 | 63 | 65 | 66 | |
| Other assets | 78 | 65 | 55 | 44 | 41 | |
| Total other assets | 1,217 | 1,109 | 833 | 752 | 794 | |
| Total assets | 2,686 | 2,419 | 2,325 | 1,664 | 1,648 | |
| Trade payables | 61 | 69 | 66 | 69 | 56 | |
| Accrued expenses | 159 | 134 | 120 | 123 | 159 | |
| Short-term operating lease liabilities | 11 | 10 | 12 | 11 | 11 | |
| Income taxes payable | 9 | 3 | 5 | 7 | 3 | |
| Total current liabilities | 240 | 216 | 204 | 221 | 236 | |
| Long-term debt | 734 | 730 | 823 | 187 | 234 | |
| Deferred income tax liabilities | 20 | 240,000 | 6 | 18 | 32 | |
| Liabilities related to unrecognized tax benefits | 2 | 2 | 2 | 2 | 932,000 | |
| Deferred compensation payable | 18 | 19 | 17 | 15 | 18 | |
| Deferred credits | 1 | 2 | 2 | 2 | 2 | |
| Long-term operating lease liabilities | 77 | 55 | 56 | 60 | 62 | |
| Other long-term obligations | 10 | 15 | 14 | 15 | 24 | |
| Total liabilities | 1,102 | 1,039 | 1,123 | 520 | 608 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock - 5,000 shares authorized; no shares issued as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, no par value - 100,000 shares authorized; issued and outstanding as of December 31, 2025 - 59,424 and December 31, 2024 - 58,743 | 764 | 703 | 638 | 675 | 642 | |
| Retained earnings | 824 | 696 | 575 | 481 | 406 | |
| Accumulated other comprehensive loss | −4 | −19 | −11 | −12 | −8 | |
| Total stockholders' equity | 1,584 | 1,379 | 1,202 | 1,144 | 1,040 | |
| Total liabilities and stockholders' equity | 2,686 | 2,419 | 2,325 | 1,664 | 1,648 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 123 | 103 | 90 | 82 | 84 | |
| Gain on disposition of business | −249,000 | — | −431,000 | 1 | — | |
| Loss on sale or abandonment of property and equipment | 2 | 1 | 6 | 380,000 | 1 | |
| Write-off of certain intangible assets and other long-term assets | 313,000 | 456,000 | 506,000 | 2 | 4 | |
| Amortization of right-of-use operating lease assets | 11 | 12 | 11 | 10 | 12 | |
| Fair value adjustments related to contingent consideration liabilities | 984,000 | 443,000 | 2 | 5 | 3 | |
| Amortization of deferred credits | −103,000 | −103,000 | −104,000 | −107,000 | −108,000 | |
| Amortization and write-off of long-term debt issuance costs | 6 | 7 | 2 | 604,000 | — | |
| Deferred income taxes | 5 | −15 | −13 | −15 | −5 | |
| Stock-based compensation expense | 43 | 28 | 21 | 18 | 16 | |
| Trade receivables | −7 | −14 | −12 | −15 | −9 | |
| Other receivables | 4 | −6 | 2 | 4 | −10 | |
| Inventories | −22 | −2 | −32 | −48 | −25 | |
| Prepaid expenses and other current assets | −3 | −4 | 1 | −2 | −4 | |
| Prepaid income taxes | −2 | 709,000 | −92,000 | −379,000 | 125,000 | |
| Income tax refund receivables | 246,000 | −2 | −58,000 | 2 | 739,000 | |
| Other assets | −2 | −6 | −6 | 657,000 | −2 | |
| Trade payables | 1 | −2 | −7 | 13 | 6 | |
| Accrued expenses | 14 | 10 | −2 | −16 | 36 | |
| Income taxes payable | 5 | −2 | −2 | 5 | −119,000 | |
| Liabilities related to unrecognized tax benefits | 80,000 | 206,000 | — | −45,000 | 314,000 | |
| Deferred compensation payable | −2 | 2 | 2 | −3 | 1 | |
| Operating lease liabilities | −11 | −12 | −11 | −11 | −12 | |
| Other long-term obligations | −947,000 | 1 | −3 | 278,000 | −858,000 | |
| Total adjustments | 169 | 100 | 51 | 40 | 99 | |
| Net cash, cash equivalents, and restricted cash provided by operating activities | 297 | 221 | 145 | 114 | 147 | |
| Property and equipment | −82 | −35 | −34 | −45 | −28 | |
| Intangible assets | −3 | −3 | −2 | −3 | −3 | |
| Proceeds from asset and business dispositions | 303,000 | 5,000 | 632,000 | — | — | |
| Cash paid for notes receivable and other investments | −18 | −10 | −5 | −1 | −2 | |
| Cash paid in acquisitions, net of cash acquired | −145 | −320 | −135 | −7 | −7 | |
| Net cash, cash equivalents, and restricted cash used in investing activities | −247 | −369 | −175 | −57 | −37 | |
| Proceeds from issuance of common stock | 28 | 41 | 16 | 20 | 21 | |
| Proceeds from issuance of long-term debt | — | — | 1,199 | 215 | 98 | |
| Payments on long-term debt | — | −99 | −580 | −260 | −207 | |
| Purchase of capped call option | — | — | −67 | — | — | |
| Long-term debt issuance costs | — | — | −677,000 | — | — | |
| Contingent payments related to acquisitions | −3 | −261,000 | −4 | −33 | −11 | |
| Payment of taxes related to an exchange of common stock | −10 | −2 | −5 | −2 | −576,000 | |
| Net cash, cash equivalents, and restricted cash provided by (used in) financing activities | 16 | −60 | 559 | −60 | −98 | |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 4 | −3 | −484,000 | −4 | −801,000 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 70 | −210 | 529 | −7 | 11 | |
| Interest (net of capitalized interest of $1,398, $1,005 and $1,272, respectively) | 21 | 23 | 14 | 6 | 5 | |
| Income taxes | 31 | 45 | 32 | 17 | 9 | |
| Property and equipment purchases in accounts payable | 3 | 13 | 8 | 4 | 3 | |
| Acquisition purchases in accrued expenses and other long-term obligations | 4 | 5 | 4 | 4 | — | |
| Right-of-use operating lease assets obtained in exchange for operating lease liabilities | 33 | 10 | 9 | 11 | 2 |